Catheter-Associated Urinary Tract Infections Treatment Global Market Report 2026

The catheter-associated urinary tract infections treatment market size has grown strongly in recent years. It will grow from $1.26 billion in 2025 to $1.33 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to increasing prevalence of catheter-associated urinary tract infections, rising hospital and clinic patient volume, adoption of antibiotics for treatment, growing healthcare infrastructure, increasing awareness of infection control measures.

The catheter-associated urinary tract infections treatment market size is expected to see strong growth in the next few years. It will grow to $1.67 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to growing adoption of urinary catheter coatings, increasing use of probiotics and immunotherapy, rising demand for personalized treatment solutions, expansion of online drug delivery and telehealth services, increasing focus on preventive care and early intervention. Major trends in the forecast period include increasing adoption of non-antibiotic therapies, rising demand for catheter coatings and antimicrobial devices, growing focus on personalized cauti treatment plans, expansion of online and retail drug distribution channels, rising awareness on early detection and prevention of cauti.

The increasing rates of hospital-acquired infections are anticipated to drive the expansion of the catheter-associated urinary tract infections treatment market in the coming years. Hospital-acquired infection rates indicate the frequency at which patients contract infections during hospital stays that were neither present nor incubating upon admission. The rise in these infections is largely attributed to antimicrobial resistance, which enables pathogens to survive standard therapies and spread more easily within healthcare facilities. Catheter-associated urinary tract infections treatment contributes to lowering hospital-acquired infections by effectively preventing and managing infections associated with indwelling catheters, thereby enhancing patient safety and reducing healthcare-related complications. For example, in May 2024, the Center for Infectious Disease Research and Policy (CIDRAP), a US-based disease research organization, reported that nearly 4.3 million patients per year acquired at least one healthcare-associated infection in hospitals across the European Union and European Economic Area in 2022 and 2023. Hence, the increasing hospital-acquired infection rates are fueling the growth of the catheter-associated urinary tract infections treatment market.

Key companies operating in the catheter-associated urinary tract infection treatment market are focusing on developing advanced solutions such as automated bladder irrigation systems to enhance infection prevention and standardization of catheter care. Automated bladder irrigation systems are a technology that controls the inflow and outflow of irrigation fluid using sensors to deliver safe and consistent cleansing cycles while reducing contamination risks through a closed system design. For example, in January 2026, UMED Inc., a South Korea-based healthcare company, showcased UroRinse Light globally at CES 2026, presenting the world’s first fully automated and standardized bladder irrigation system designed for long-term urinary catheter users. The system uses sensor-based automated control to manage irrigation flow and ensure reproducible treatment cycles while minimizing contamination through a closed structure. It enables use across hospitals, care facilities, and home settings, allowing patients and caregivers to perform safe and repeatable bladder irrigation outside traditional clinical environments. The device integrates with a mobile application and cloud database to record irrigation history and monitor patient status, with planned integration into electronic medical record (EMR) systems and remote care platforms to support continuous monitoring and proactive infection prevention.

The expanding geriatric population is projected to boost the growth of the catheter-associated urinary tract infection treatment market in the future. The geriatric population encompasses older adults, generally aged 65 years and above, who often need specialized healthcare and social support due to age-related physical, mental, and functional changes. The growth of this population is driven by longer life expectancy, as advancements in healthcare, nutrition, and living conditions allow people to live longer, resulting in a larger proportion of older adults. Catheter-associated urinary tract infection treatment benefits the geriatric population by minimizing infection-related complications, enhancing urinary function, and improving overall quality of life. For instance, in July 2024, the UK Parliament's House of Commons Library, a UK-based government institution, indicated that the number of people aged 65 or older in the UK was 12.7 million in 2022, representing 19% of the total population, and is expected to reach 22.1 million by 2072, accounting for 27% of the population. Therefore, the growing geriatric population is contributing to the expansion of the catheter-associated urinary tract infection treatment market.

Major companies operating in the catheter-associated urinary tract infections treatment market are Cardinal Health Inc., Pfizer Incorporated, Bayer Aktiengesellschaft, AstraZeneca Public Limited Company, Medline Industries, Limited Partnership, Becton, Dickinson Company, B. Braun Societät mit beschränkter Haftung, Merck Company Inc, Coloplast A/S, Teleflex Incorporated, ConvaTec Group Public Limited Company, Hollister Incorporated, Vygon S.A., Wellspect Healthcare AB, Urocare Products Inc, Paul Hartmann Aktiengesellschaft, Bactiguard AB, NanoVibronix Inc, WellLead Medical Co Limited, Poiesis Medical LLC.

North America was the largest region in the catheter-associated urinary tract infections treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the catheter-associated urinary tract infections treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the catheter-associated urinary tract infections treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The catheter-associated urinary tract infection treatment market consists of revenues earned by entities by providing services such as catheter maintenance and monitoring services, diagnostic testing and laboratory services, clinical consultation and treatment management, telehealth monitoring, and wound and urinary tract care management. The market value includes the value of related goods sold by the service provider or included within the service offering. The catheter-associated urinary tract infection treatment market also includes sales of catheter maintenance and closed drainage systems, catheter care kits and auxiliary devices, catheter care kits and auxiliary devices, hydrophilic‑coated catheters, and catheter securing devices and stabilizers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Catheter-associated urinary tract infection (CAUTI) treatment involves the clinical management of urinary tract infections occurring in patients with an indwelling urinary catheter, with the goal of eliminating infection, easing symptoms, and avoiding complications. Management generally includes prompt removal or replacement of the catheter when feasible, targeted antimicrobial therapy guided by clinical evaluation and urine culture findings, supportive care measures, and addressing underlying risk factors to prevent recurrence.

The key treatment types of catheter-associated urinary tract infections include antibiotics and non-antibiotic therapies. Antibiotics are used to prevent or treat bacterial infections associated with catheter use. Treatments include penicillin and combinations, quinolones, cephalosporins, aminoglycosides, sulphonamides, azoles and amphotericin B, tetracyclines, nitrofurans, and other drug types, indicated for asymptomatic and symptomatic CAUTI. Distribution occurs via hospital pharmacies, gynecology and urology clinics, drug stores, retail pharmacies, and online stores, serving clinics, hospitals, and other end-users.

Tariffs on imported antibiotics, catheter coatings, and related medical devices are impacting the CAUTI treatment market by raising costs for hospitals, clinics, and retail pharmacies, particularly affecting penicillin, cephalosporin, and coated catheter segments. Regions such as North America, Europe, and Asia-Pacific, which rely heavily on imported drugs and medical devices, are most affected. While tariffs increase procurement costs, they also encourage domestic manufacturing, drive innovation in cost-effective catheter coatings and therapies, and promote local supply chain resilience, benefiting regional market growth.

The catheter-associated urinary tract infections treatment market research report is one of a series of new reports that provides catheter-associated urinary tract infections treatment market statistics, including catheter-associated urinary tract infections treatment industry global market size, regional shares, competitors with a catheter-associated urinary tract infections treatment market share, detailed catheter-associated urinary tract infections treatment market segments, market trends and opportunities, and any further data you may need to thrive in the catheter-associated urinary tract infections treatment industry. This catheter-associated urinary tract infections treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.